DRAGARWQBSEDr Agarwals Eye Hospital Ltd-$HighNeutral
Announced Wed, 20 May · 18:27 IST

Audited Financial Results of the Company for the quarter and year ended March 31, 2026, is attached.

Pat Growth 25pctEbitda Margin ExpansionRelated Party TransactionsResults View source PDF

DRAGARWQ · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.6%1-day move
₹5150.00
prior close
₹5170.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-3.3-4.5-1.7+0.6-3.5+0.0-0.2-1.4-2.2-3.4-3.1-3.2
Up moveDown movePending
AI summary

Dr Agarwal's Eye Hospital reported strong FY26 results with revenue from operations growing 18.6% YoY to ₹470.87 crore from ₹397.15 crore. Net profit after tax rose 28.3% to ₹70.10 crore versus ₹54.65 crore in the prior year. Q4 revenue stood at ₹120.01 crore with net profit of ₹16.24 crore. EBITDA for the full year was approximately ₹150.82 crore (31.5% margin), up from ₹123.09 crore (31% margin) in FY25. EPS improved to ₹147.02 per share from ₹116.28. The company recommended a final dividend of ₹4 per share, bringing total FY26 dividend to ₹7 per share (70%) including the ₹3 interim dividend already paid. Statutory auditors S.R. Batliboi & Associates issued an unmodified (clean) audit opinion. The Board also approved a scheme of amalgamation with holding company Dr. Agarwal's Health Care Limited, pending shareholder and regulatory approvals.

Likely market impact

Strong financial performance with near 28% PAT growth and solid operating cash flows of ₹145 crore signals healthy business momentum. The 70% total dividend payout demonstrates shareholder-friendly policies. Clean audit opinion removes concerns about financial reporting quality, which is positive for investor confidence.